INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44m ago
HOUSE PTR3m ago
SEC 13F3m ago
ROBINHOOD CHAIN3m ago
Public company

DNTHDianthus Therapeutics, Inc. /DE/

CIK 0001690585

EDGAR filingsOpen in network
Disclosed transactions60
Buys / sells0 / 24
Max Insider Score36
Connections6with evidence

DNTH · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
6,249 sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    McGeorge AnneDirector · Aug 11, 2026
  • ← Insider ofevidence
    Veness Adam MSVP, General Counsel and Sec. · Aug 11, 2026
  • ← Insider ofevidence
    Soteropoulos PaulaDirector · Mar 26, 2026
19
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL
$1.42M
13.3K sh
Sep 1, 2026
Sep 3, 2026
traded Sep 1, 2026
+2d
SEC FORM 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
7,500 sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

7
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$134K
7,500 sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
9,375 sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

7
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$136K
6,249 sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

7
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$207K
9,375 sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

8
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$273K
2,600 sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

12
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$767K
7,215 sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

11
VM
Veness Adam MSVP, General Counsel and Sec.
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise
M$273K
15.0K sh
Aug 13, 2026Aug 14, 2026
traded Aug 13, 2026
+1dSEC FORM 4

Evidence

13
VM
Veness Adam MSVP, General Counsel and Sec.
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise
M—
15.0K sh
Aug 13, 2026Aug 14, 2026
traded Aug 13, 2026
+1dSEC FORM 4

Evidence

0
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$24K
1,250 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

0
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
1,250 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

25
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$111K
1,000 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

25
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$78K
700 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

28
VM
Veness Adam MSVP, General Counsel and Sec.
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$356K
3,217 sh
Aug 7, 2026Aug 11, 2026
traded Aug 7, 2026
+4dSEC FORM 4

Evidence

2
VM
Veness Adam MSVP, General Counsel and Sec.
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$69K
3,833 sh
Aug 7, 2026Aug 11, 2026
traded Aug 7, 2026
+4dSEC FORM 4

Evidence

0
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
6,500 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

1
VM
Veness Adam MSVP, General Counsel and Sec.
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$289K
16.2K sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

25
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$197K
1,800 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

24
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$303K
2,800 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

17
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$156K
1,450 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

14
MA
McGeorge AnneDirector
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$73K
6,500 sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

3
VM
Veness Adam MSVP, General Counsel and Sec.
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
3,833 sh
Aug 7, 2026Aug 11, 2026
traded Aug 7, 2026
+4dSEC FORM 4

Evidence

25
VM
Veness Adam MSVP, General Counsel and Sec.
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$68K
616 sh
Aug 7, 2026Aug 11, 2026
traded Aug 7, 2026
+4dSEC FORM 4

Evidence

3
VM
Veness Adam MSVP, General Counsel and Sec.
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
16.2K sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

27
VM
Veness Adam MSVP, General Counsel and Sec.
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$1.78M
16.2K sh
Aug 10, 2026Aug 11, 2026
traded Aug 10, 2026
+1dSEC FORM 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
9,375 sh
Jun 1, 2026Jun 2, 2026
traded Jun 1, 2026
+1dSEC FORM 4

Evidence

22
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$1.54M
16.9K sh
Jun 1, 2026Jun 2, 2026
traded Jun 1, 2026
+1dSEC FORM 4

Evidence

7
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$34K
3,998 sh
Jun 1, 2026Jun 2, 2026
traded Jun 1, 2026
+1dSEC FORM 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
3,998 sh
Jun 1, 2026Jun 2, 2026
traded Jun 1, 2026
+1dSEC FORM 4

Evidence

19
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$380K
4,159 sh
Jun 1, 2026Jun 2, 2026
traded Jun 1, 2026
+1dSEC FORM 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
6,249 sh
Jun 1, 2026Jun 2, 2026
traded Jun 1, 2026
+1dSEC FORM 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
6,908 sh
Jun 1, 2026Jun 2, 2026
traded Jun 1, 2026
+1dSEC FORM 4

Evidence

10
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$124K
6,908 sh
Jun 1, 2026Jun 2, 2026
traded Jun 1, 2026
+1dSEC FORM 4

Evidence

6
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$136K
6,249 sh
Jun 1, 2026Jun 2, 2026
traded Jun 1, 2026
+1dSEC FORM 4

Evidence

6
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$207K
9,375 sh
Jun 1, 2026Jun 2, 2026
traded Jun 1, 2026
+1dSEC FORM 4

Evidence

11
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$487K
5,428 sh
Jun 1, 2026Jun 2, 2026
traded Jun 1, 2026
+1dSEC FORM 4

Evidence

16
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$739K
8,224 sh
Apr 9, 2026Apr 10, 2026
traded Apr 9, 2026
+1dSEC FORM 4

Evidence

0
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$147K
8,224 sh
Apr 9, 2026Apr 10, 2026
traded Apr 9, 2026
+1dSEC FORM 4

Evidence

0
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
8,224 sh
Apr 9, 2026Apr 10, 2026
traded Apr 9, 2026
+1dSEC FORM 4

Evidence

7
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
40.0K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

0
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
74.4K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

1
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$628K
74.4K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

24
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$619K
7,232 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

27
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$1.65M
19.5K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

27
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$5.02M
59.8K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

9
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$196K
2,366 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

9
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$65K
800 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

9
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$119K
1,485 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

19
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$1.72M
21.8K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

9
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$109K
1,390 sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

13
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$715K
40.0K sh
Mar 31, 2026Apr 1, 2026
traded Mar 31, 2026
+1dSEC FORM 4

Evidence

36
SP
Soteropoulos PaulaDirector
DNTHDianthus Therapeutics, Inc. /DE/
Open-market sale · 10b5-1 plan
SELL$2.15M
27.6K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC FORM 4

Evidence

2
SP
Soteropoulos PaulaDirector
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$233K
27.6K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC FORM 4

Evidence

0
SP
Soteropoulos PaulaDirector
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
27.6K sh
Mar 24, 2026Mar 26, 2026
traded Mar 24, 2026
+2dSEC FORM 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$68K
7,998 sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC FORM 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
12.5K sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC FORM 4

Evidence

0
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M—
5,000 sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC FORM 4

Evidence

10
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Option exercise · 10b5-1 plan
M$89K
5,000 sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC FORM 4

Evidence

← Insider ofevidence
Savitz Ryan
CFO & CBO · Dec 5, 2025
  • ← Insider ofevidence
    Randhawa SimratEVP, Head of R&D · Nov 14, 2025